Literature DB >> 29777836

Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report.

N Hoyle1, P Zhvaniya2, N Balarjishvili3, D Bolkvadze3, L Nadareishvili2, D Nizharadze2, J Wittmann4, C Rohde4, M Kutateladze3.   

Abstract

Respiratory infections can lead to serious complications in CF patients, especially when infected with antibiotic resistant bacteria. Alternative treatments for these infections are being sought out to help address this problem. We present a clinical case of a cystic fibrosis (CF) patient, with multi-drug resistant (MDR) Achromobacter xylosoxidans chronic lung infection who was successfully managed with bacteriophage therapy.
Copyright © 2018. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Achromobacter xylosoxidans; Antibiotic resistance; Bacteriophage; Cystic fibrosis; Phage therapy; Respiratory infection

Mesh：

Substances：

Year:  2018        PMID： 29777836     DOI： 10.1016/j.resmic.2018.05.001

Source DB:  PubMed          Journal:  Res Microbiol        ISSN： 0923-2508            Impact factor:   3.992


  26 in total

1.  Methods for Extraction and Detection of Pf Bacteriophage DNA from the Sputum of Patients with Cystic Fibrosis.

Authors:  Elizabeth B Burgener; Patrick R Secor; Michael C Tracy; Johanna M Sweere; Elisabeth M Bik; Carlos E Milla; Paul L Bollyky
Journal:  Phage (New Rochelle)       Date:  2020-06-16

2.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

Review 3.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

4.  Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.

Authors:  Yu Lin; Diana Quan; Rachel Yoon Kyung Chang; Michael Y T Chow; Yuncheng Wang; Mengyu Li; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2020-11-27       Impact factor: 5.571

5.  Use of a Primary Epithelial Cell Screening Tool to Investigate Phage Therapy in Cystic Fibrosis.

Authors:  Stephanie Trend; Barbara J Chang; Mark O'Dea; Stephen M Stick; Anthony Kicic
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810

Review 6.  Towards Inhaled Phage Therapy in Western Europe.

Authors:  Sandra-Maria Wienhold; Jasmin Lienau; Martin Witzenrath
Journal:  Viruses       Date:  2019-03-23       Impact factor: 5.048

Review 7.  Phage-Antibiotic Combination Treatments: Antagonistic Impacts of Antibiotics on the Pharmacodynamics of Phage Therapy?

Authors:  Stephen T Abedon
Journal:  Antibiotics (Basel)       Date:  2019-10-11

Review 8.  An Appraisal of Bacteriophage Isolation Techniques from Environment.

Authors:  Aparna Nair; Gaurav S Ghugare; Krishna Khairnar
Journal:  Microb Ecol       Date:  2021-06-17       Impact factor: 4.552

Review 9.  Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria.

Authors:  Christine Rohde; Johannes Wittmann; Elizabeth Kutter
Journal:  Surg Infect (Larchmt)       Date:  2018-10-09       Impact factor: 2.150

Review 10.  Animal Models to Translate Phage Therapy to Human Medicine.

Authors:  Alessia Brix; Marco Cafora; Massimo Aureli; Anna Pistocchi
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.